Effect of food on the pharmacokinetics of lurasidone: Results of two randomized, open-label, crossover studies

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 495-505

  Preskorn, Sheldon ^a   Ereshefsky, Larry ^b,c   Chiu, Yu Yuan ^d   Poola, Nagaraju ^d   Loebel, Antony ^d  

^a University of Montreal   (United States)

^b PAREXEL INTERNATIONAL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

absorption; food; lurasidone; pharmacokinetics; schizophrenia

Indexed keywords

LURASIDONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; FAT CONTENT; FEMALE; FOOD INTAKE; HUMAN; LIPID COMPOSITION; LIPID DIET; LOW FAT DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS;

ABSORPTION; FOOD; LURASIDONE; PHARMACOKINETICS; SCHIZOPHRENIA;

ADULT; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; SCHIZOPHRENIA; THIAZOLES;

EID: 84884152752     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2338     Document Type: Article

References (30)

1. Abilify® (aripiprazole) tablets [prescribing information]. 2012. Princeton, NJ: Bristol-Myers Squibb Company.
2. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th edn., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press,.
3. Citrome L., 2011. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 65: 189-210.
4. Citrome L., 2012. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses 6: 76-85.
5. DeVane CL, Nemeroff CB,. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40: 509-522.
6. Fleisher D, Li C, Zhou Y, Pao LH, Karim A,. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36: 233-254.
7. Gandelman K, Alderman JA, Glue P, et al,. 2009. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry 70: 58-62.
8. Hamelin BA, Allard S, Laplante L, et al,. 1998. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18: 9-15.
9. Invega® (paliperidone) extended-release tablets [prescribing information]. 2011. Titusville, NJ: Janssen Pharmaceuticals, Inc.
10. Invega® (paliperidone) prolonged-release tablets [summary of product characteristics]. 2011. Beerse, Belgium: Janssen-Cilag International NV.
11. 1A receptor activity. J Pharmacol Exp Ther 334: 171-181.
12. Latuda® (lurasidone HCl) tablets [prescribing information]. 2012. Marlborough, MA: Sunovion Pharmaceuticals Inc.
13. Lincoln J, Stewart ME, Preskorn SH,. 2010. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. J Psychiatr Pract 16: 103-114.
14. Loebel A, Cucchiaro J, Sarma K, et al,. 2013. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 145: 101-109.
15. Meltzer HY, Cucchiaro J, Silva R, et al,. 2011. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 168: 957-967.
16. Meyer JM, Loebel AD, Schweizer E,. 2009. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18: 1715-1726.
17. Miceli JJ, Glue P, Alderman J, Wilner K,. 2007. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull 40: 58-68.
18. Nakamura M, Ogasa M, Guarino J, et al,. 2009. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70: 829-836.
19. Ogasa M, Kimura T, Nakamura M, Guarino J,. 2013. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 225: 519-530.
20. Posner K, Brown GK, Stanley B, et al,. 2011. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266-1277.
21. Risperdal® (risperidone) tablets [prescribing information]. 2011. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.
22. Schmidt LE, Dalhoff K,. 2002. Food-drug interactions. Drugs 62: 1481-1502.
23. Seroquel XR® (quetiapine fumarate) extended-release tablets [prescribing information]. 2012. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
24. Singh BN,. 1999. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37: 213-255.
25. Svensson CK, Edwards DJ, Mauriello PM, et al,. 1983. Effect of food on hepatic blood flow: implications in the "food effect" phenomenon. Clin Pharmacol 34: 316-323.
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2001. Guidance for industry, bioanalytical method validation. Drug Information Branch, Center for Drug Evaluation and Research: Rockville, MD.
27. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2002. Guidance for Industry, Food-Effect Bioavailability and Fed Bioequivalence Studies. Office of Training and Communications, Division of Drug Information: Rockville, MD.
28. Williams EJ,. 1949. Experimental designs balanced for the estimation of residual effects of treatments. Aus J Sci Res (Ser a) 2: 149-168.
29. Winstanley PA, Orme ML,. 1989. The effects of food on drug bioavailability. Br J Clin Pharmacol 28: 621-628.
30. Zyprexa® (olanzapine) tablet for oral use [prescribing information]. 2011. Indianapolis, IN: Lilly USA, LLC.